PharmaCorp Rx Inc.
PCRX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.07M | 122.70K | -281.00K | -429.90K | -757.30K |
| Total Depreciation and Amortization | 673.50K | 565.10K | 459.30K | 339.40K | 208.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 304.90K | -305.50K | 89.70K | 99.70K | 113.80K |
| Change in Net Operating Assets | 1.54M | 768.50K | 12.00K | 290.90K | 504.10K |
| Cash from Operations | 1.44M | 1.15M | 280.10K | 300.10K | 69.40K |
| Capital Expenditure | -55.70K | -41.80K | -1.55M | -23.70K | -5.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -9.14M | -18.79M | -12.88M | -12.08M | -12.08M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -730.90K | -- | -- | -- | -- |
| Cash from Investing | -9.93M | -18.83M | -14.43M | -12.10M | -12.09M |
| Total Debt Issued | 3.16M | -- | -- | -- | -- |
| Total Debt Repaid | -323.00K | -213.30K | -193.00K | -157.80K | -107.10K |
| Issuance of Common Stock | 24.60M | 3.16M | 7.64M | 27.49M | 27.49M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 431.80K | -18.20K | -- | -- | -- |
| Cash from Financing | 17.75M | 2.13M | 5.46M | 20.00M | 20.03M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.26M | -15.55M | -8.69M | 8.19M | 8.02M |